Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR)
United Arab Emirates
· Delayed Price · Currency is AED 1.250
-0.020 (-1.57%)
Last updated: Apr 23, 2025
ADX:JULPHAR Income Statement
Financials in millions AED. Fiscal year is January - December.
Millions AED. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 1,313 | 1,278 | 1,616 | 1,143 | 573 | Upgrade
|
| Revenue Growth (YoY) | 2.74% | -20.95% | 41.37% | 99.51% | 90.05% | Upgrade
|
| Cost of Revenue | 793.4 | 852.4 | 1,058 | 759.8 | 387.9 | Upgrade
|
| Gross Profit | 519.1 | 425.1 | 557.9 | 383.4 | 185.1 | Upgrade
|
| Selling, General & Admin | 454.5 | 458.3 | 596.3 | 451.9 | 397 | Upgrade
|
| Other Operating Expenses | -10.4 | -8.7 | -9.8 | -110 | -3.9 | Upgrade
|
| Operating Expenses | 444.1 | 449.6 | 586.5 | 341.9 | 393.1 | Upgrade
|
| Operating Income | 75 | -24.5 | -28.6 | 41.5 | -208 | Upgrade
|
| Interest Expense | -62.2 | -56.3 | -40.1 | -23.7 | -34 | Upgrade
|
| Interest & Investment Income | 2.6 | 6 | 3.6 | 2.4 | 2.1 | Upgrade
|
| Earnings From Equity Investments | - | - | - | -31.4 | 6.1 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.7 | - | 0.2 | - | - | Upgrade
|
| EBT Excluding Unusual Items | 16.1 | -74.8 | -64.9 | -11.2 | -233.8 | Upgrade
|
| Gain (Loss) on Sale of Investments | 3.3 | 3.5 | 2 | -5.5 | -2 | Upgrade
|
| Asset Writedown | -1.5 | - | - | - | -37.7 | Upgrade
|
| Other Unusual Items | 0.8 | -1.6 | 29.5 | 59.3 | - | Upgrade
|
| Pretax Income | 18.7 | -72.9 | -33.4 | 42.6 | -273.5 | Upgrade
|
| Income Tax Expense | 3.7 | 6.1 | 2.8 | 1.1 | -1.8 | Upgrade
|
| Earnings From Continuing Operations | 15 | -79 | -36.2 | 41.5 | -271.7 | Upgrade
|
| Earnings From Discontinued Operations | 29.9 | -19.5 | 4.5 | 17.9 | -45.7 | Upgrade
|
| Net Income to Company | 44.9 | -98.5 | -31.7 | 59.4 | -317.4 | Upgrade
|
| Minority Interest in Earnings | -0.3 | -0.6 | 2.3 | 5 | 24.2 | Upgrade
|
| Net Income | 44.6 | -99.1 | -29.4 | 64.4 | -293.2 | Upgrade
|
| Net Income to Common | 44.6 | -99.1 | -29.4 | 64.4 | -293.2 | Upgrade
|
| Shares Outstanding (Basic) | 1,155 | 1,155 | 1,155 | 1,155 | 1,058 | Upgrade
|
| Shares Outstanding (Diluted) | 1,155 | 1,155 | 1,155 | 1,155 | 1,058 | Upgrade
|
| Shares Change (YoY) | - | - | - | 9.21% | 61.46% | Upgrade
|
| EPS (Basic) | 0.04 | -0.09 | -0.03 | 0.06 | -0.28 | Upgrade
|
| EPS (Diluted) | 0.04 | -0.09 | -0.03 | 0.06 | -0.28 | Upgrade
|
| Free Cash Flow | 201.3 | 71.5 | -44.4 | 1.8 | -184.3 | Upgrade
|
| Free Cash Flow Per Share | 0.17 | 0.06 | -0.04 | 0.00 | -0.17 | Upgrade
|
| Gross Margin | 39.55% | 33.28% | 34.52% | 33.54% | 32.30% | Upgrade
|
| Operating Margin | 5.71% | -1.92% | -1.77% | 3.63% | -36.30% | Upgrade
|
| Profit Margin | 3.40% | -7.76% | -1.82% | 5.63% | -51.17% | Upgrade
|
| Free Cash Flow Margin | 15.34% | 5.60% | -2.75% | 0.16% | -32.16% | Upgrade
|
| EBITDA | 167.2 | 74.9 | 66.5 | 128.5 | -109.7 | Upgrade
|
| EBITDA Margin | 12.74% | 5.86% | 4.12% | 11.24% | -19.14% | Upgrade
|
| D&A For EBITDA | 92.2 | 99.4 | 95.1 | 87 | 98.3 | Upgrade
|
| EBIT | 75 | -24.5 | -28.6 | 41.5 | -208 | Upgrade
|
| EBIT Margin | 5.71% | -1.92% | -1.77% | 3.63% | -36.30% | Upgrade
|
| Effective Tax Rate | 19.79% | - | - | 2.58% | - | Upgrade
|
Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.